1. Home
  2. STHO vs LPTX Comparison

STHO vs LPTX Comparison

Compare STHO & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STHO
  • LPTX
  • Stock Information
  • Founded
  • STHO N/A
  • LPTX 2011
  • Country
  • STHO United States
  • LPTX United States
  • Employees
  • STHO N/A
  • LPTX N/A
  • Industry
  • STHO Real Estate
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • STHO Real Estate
  • LPTX Health Care
  • Exchange
  • STHO Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • STHO 117.1M
  • LPTX 119.6M
  • IPO Year
  • STHO N/A
  • LPTX N/A
  • Fundamental
  • Price
  • STHO $8.85
  • LPTX $0.48
  • Analyst Decision
  • STHO
  • LPTX Buy
  • Analyst Count
  • STHO 0
  • LPTX 3
  • Target Price
  • STHO N/A
  • LPTX $8.50
  • AVG Volume (30 Days)
  • STHO 64.7K
  • LPTX 1.5M
  • Earning Date
  • STHO 02-18-2025
  • LPTX 03-17-2025
  • Dividend Yield
  • STHO N/A
  • LPTX N/A
  • EPS Growth
  • STHO N/A
  • LPTX N/A
  • EPS
  • STHO N/A
  • LPTX N/A
  • Revenue
  • STHO $113,297,000.00
  • LPTX N/A
  • Revenue This Year
  • STHO N/A
  • LPTX N/A
  • Revenue Next Year
  • STHO N/A
  • LPTX N/A
  • P/E Ratio
  • STHO N/A
  • LPTX N/A
  • Revenue Growth
  • STHO N/A
  • LPTX N/A
  • 52 Week Low
  • STHO $7.96
  • LPTX $0.47
  • 52 Week High
  • STHO $14.50
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • STHO 49.86
  • LPTX 19.00
  • Support Level
  • STHO $8.59
  • LPTX $0.47
  • Resistance Level
  • STHO $8.96
  • LPTX $0.53
  • Average True Range (ATR)
  • STHO 0.30
  • LPTX 0.04
  • MACD
  • STHO 0.08
  • LPTX 0.07
  • Stochastic Oscillator
  • STHO 86.47
  • LPTX 7.42

About STHO Star Holdings Shares of Beneficial Interest

Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: